1. Home
  2. ATNI vs ENGN Comparison

ATNI vs ENGN Comparison

Compare ATNI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

HOLD

Current Price

$27.84

Market Cap

406.5M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.81

Market Cap

115.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNI
ENGN
Founded
1987
1999
Country
United States
Canada
Employees
N/A
82
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
406.5M
115.9M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
ATNI
ENGN
Price
$27.84
$1.81
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
55.9K
3.4M
Earning Date
05-06-2026
06-11-2026
Dividend Yield
4.03%
N/A
EPS Growth
34.29
N/A
EPS
N/A
N/A
Revenue
$727,975,000.00
N/A
Revenue This Year
$3.12
N/A
Revenue Next Year
$1.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.86
$1.40
52 Week High
$30.45
$12.25

Technical Indicators

Market Signals
Indicator
ATNI
ENGN
Relative Strength Index (RSI) 57.39 29.69
Support Level $22.76 $1.40
Resistance Level $29.24 $7.33
Average True Range (ATR) 1.05 0.13
MACD 0.17 0.11
Stochastic Oscillator 74.64 93.46

Price Performance

Historical Comparison
ATNI
ENGN

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: